Atrium Therapeutics, Inc. (NASDAQ: RNA) is a Healthcare company (Biotechnology) with a market capitalization of $140M. The Maz Rating grades it against the other companies in its sector.
Atrium Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.48, Atrium Therapeutics, Inc. trades at 655.1x sales and 6.4x book value. Over the last twelve months it generated about $213388 of revenue and a net loss of $8M. It runs a gross margin of 80.4%, an operating margin of -3576.0% and a net margin of -3310.8%. It shows return on equity of -35.8%, return on invested capital of -34.8% and a free cash flow yield of -4.8%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 9.20. Over the past 52 weeks the share price ranged from $6.36 to $16.77, with a beta of 0.37.
Atrium Therapeutics, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 8 Buy and 8 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.